James Stambaugh, VP Clinical Affairs & Reimb at Intersect ENT, Inc. (XENT), sold 8,343 shares at $20.98 ($175K) on 2015-02-02, disclosed to the SEC on 2015-02-03.
Scheduled sale ($175k) by VP Clinical Affairs & Reimb under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| XENT | SELL | 2016-07-19 | $77K | — | Filing → |
| XENT | SELL | 2016-06-14 | $7K | — | Filing → |
| XENT | SELL | 2015-07-21 | $366K | — | Filing → |